Literature DB >> 26303290

New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future.

Bertram Pitt1, George L Bakris2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26303290     DOI： 10.1161/HYPERTENSIONAHA.115.04889

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  20 in total

Review 1.  Basolateral Kir4.1 activity in the distal convoluted tubule regulates K secretion by determining NaCl cotransporter activity.

Authors:  Wen-Hui Wang
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-09       Impact factor: 2.894

Review 2.  Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

Authors:  Collen Majewski; George L Bakris
Journal:  Curr Diab Rep       Date:  2016-04       Impact factor: 4.810

3.  Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Authors:  Luis M Ruilope; Rajiv Agarwal; Stefan D Anker; George L Bakris; Gerasimos Filippatos; Christina Nowack; Peter Kolkhof; Amer Joseph; Nicole Mentenich; Bertram Pitt
Journal:  Am J Nephrol       Date:  2019-10-30       Impact factor: 3.754

4.  The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population.

Authors:  Nihar R Desai; Pamala Reed; Paula J Alvarez; Jeanene Fogli; Steven D Woods; Mary Kay Owens
Journal:  Am Health Drug Benefits       Date:  2019-11

Review 5.  The cardiovascular-dialysis nexus: the transition to dialysis is a treacherous time for the heart.

Authors:  Kevin Chan; Sharon M Moe; Rajiv Saran; Peter Libby
Journal:  Eur Heart J       Date:  2021-03-31       Impact factor: 29.983

6.  Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice.

Authors:  James P Davidson; Andrew J King; Padmapriya Kumaraswamy; Jeremy S Caldwell; Paul Korner; Robert C Blanks; Jeffrey W Jacobs
Journal:  J Cardiovasc Pharmacol Ther       Date:  2017-11-12       Impact factor: 2.457

7.  Treatment of Mild Hyperkalemia in Hospitalized Patients: An Unnecessary Practice?

Authors:  Tracy A Freeze; Leanne Skerry; Emily Kervin; Rosemary Nunn; Jennifer Woodland; Natasha Hanson; Martin MacKinnon
Journal:  Can J Hosp Pharm       Date:  2021-07-01

8.  Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial.

Authors:  George L Bakris; Steven D Woods; Paula J Alvarez; Susan P Arthur; Rajeev Kumar
Journal:  Kidney Med       Date:  2021-03-13

9.  Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study.

Authors:  Sandra Wagner; Marie Metzger; Martin Flamant; Pascal Houillier; Jean-Philippe Haymann; François Vrtovsnik; Eric Thervet; Jean-Jacques Boffa; Ziad A Massy; Bénédicte Stengel; Patrick Rossignol
Journal:  BMC Nephrol       Date:  2017-09-12       Impact factor: 2.388

10.  Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.

Authors:  Bertram Pitt; George L Bakris; Matthew R Weir; Mason W Freeman; Mitja Lainscak; Martha R Mayo; Dahlia Garza; Rezi Zawadzki; Lance Berman; David A Bushinsky
Journal:  ESC Heart Fail       Date:  2018-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.